Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Marc Lambelet"'
Autor:
Carlos Arturo Areán Martínez, Fernando Lanas, Ghazi Radaideh, Suleiman M. Kharabsheh, Marc Lambelet, Marco Antonio Lavagnino Viaud, Naser Samih Ziadeh, Alexander G.G. Turpie
Publikováno v:
The Egyptian Heart Journal, Vol 70, Iss 4, Pp 307-313 (2018)
Background: The prospective, observational XANTUS study demonstrated low rates of stroke and major bleeding in real-world rivaroxaban-treated patients with non-valvular atrial fibrillation (NVAF) from Western Europe, Canada and Israel. XANTUS-EL is a
Externí odkaz:
https://doaj.org/article/165b4d75611b42be965053033c63de40
Autor:
Paulus Kirchhof, Sylvia Haas, Pierre Amarenco, Susanne Hess, Marc Lambelet, Martin van Eickels, Alexander G. G. Turpie, A. John Camm
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 9, Iss 5 (2020)
Background Reducing major bleeding events is a challenge when managing anticoagulation in patients with atrial fibrillation. This study evaluated the impact of modifiable and nonmodifiable bleeding risk factors in patients with atrial fibrillation re
Externí odkaz:
https://doaj.org/article/b423e0577eca4d11b7316a35c4116953
Autor:
Olivier Sitbon, Christian Meier, Raymond L. Benza, Marc Lambelet, Adaani E. Frost, Sylvia Nikkho, Marius M. Hoeper, Athénaïs Boucly, Hossein Ardeschir Ghofrani, Sameer Bansilal, Harrison W. Farber, Claudia Rahner
Publikováno v:
The Journal of Heart and Lung Transplantation. 41:411-420
BACKGROUND Risk assessment is essential in pulmonary arterial hypertension (PAH) management. We investigated the effect of riociguat on REVEAL Lite 2 score, an abridged version of the REVEAL risk score, and its association with long-term outcomes in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0140bec243ee9bb8f3ccdfa2e9e14223
https://doi.org/10.1016/j.healun.2021.10.013
https://doi.org/10.1016/j.healun.2021.10.013
Autor:
Peter, Rossing, Rajiv, Agarwal, Stefan D, Anker, Gerasimos, Filippatos, Bertram, Pitt, Luis M, Ruilope, Vivian, Fonseca, Guillermo E, Umpierrez, Maria Luiza, Caramori, Amer, Joseph, Marc, Lambelet, Robert, Lawatscheck, George L, Bakris
Publikováno v:
the FIDELIO-DKD and FIGARO-DKD investigators 2023, ' Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon-like peptide-1 receptor agonist use ', Diabetes, Obesity and Metabolism, vol. 25, no. 2, pp. 407-416 . https://doi.org/10.1111/dom.14883
AimsTo explore the modifying effect of glucagon-like peptide-1 receptor agonist (GLP-1RA) use on outcomes with finerenone across a wide spectrum of patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) in the pooled analysis of FIDELIO
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eebcad350786a56f6cf8def242306db8
https://curis.ku.dk/ws/files/359728926/Diabetes_Obesity_Metabolism_2022_Rossing_Finerenone_in_patients_across_the_spectrum_of_chronic_kidney_disease_and.pdf
https://curis.ku.dk/ws/files/359728926/Diabetes_Obesity_Metabolism_2022_Rossing_Finerenone_in_patients_across_the_spectrum_of_chronic_kidney_disease_and.pdf
Autor:
Rajiv Agarwal, Luis M. Ruilope, Gema Ruiz-Hurtado, Hermann Haller, Roland E. Schmieder, Stefan D. Anker, Gerasimos Filippatos, Bertram Pitt, Peter Rossing, Marc Lambelet, Christina Nowack, Peter Kolkhof, Amer Joseph, George L Bakris
Publikováno v:
Journal of hypertension. 41(2)
Finerenone is a selective nonsteroidal mineralocorticoid receptor antagonist with a short half-life. Its effects on cardiorenal outcomes were thought to be mediated primarily via nonhemodynamic pathways, but office blood pressure (BP) measurements we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf5b9c5b3d3d4e5cfa371a52b287b6c4
https://pubmed.ncbi.nlm.nih.gov/36583355
https://pubmed.ncbi.nlm.nih.gov/36583355
Autor:
null Peter Rossing, null Rajiv Agarwal, null Stefan D. Anker, null Gerasimos Filippatos, null Bertram Pitt, null Luis M. Ruilope, null Vivian Fonseca, null Guillermo E. Umpierrez, null Maria Luiza Caramori, null Amer Joseph, null Marc Lambelet, null Robert Lawatscheck, null George L. Bakris, null the FIDELIO‐DKD and FIGARO‐DKD Investigators
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::337e535a3d4c66097a32c6335a5f92c9
https://doi.org/10.1111/dom.14883/v2/response1
https://doi.org/10.1111/dom.14883/v2/response1
Autor:
Sylvia Nikkho, Marius M. Hoeper, Raymond L. Benza, Adaani E. Frost, Christian Meier, Paul A. Corris, Hossein Ardeschir Ghofrani, Marc Lambelet, Harrison W. Farber
Publikováno v:
International Journal of Cardiology. 332:189-192
Regular risk assessment is recommended in pulmonary arterial hypertension (PAH) management to improve patient outcomes. The REVEAL risk score (RRS) predicts survival in patients with PAH, including those from the PATENT study, which assessed riocigua
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea8d58710ed1a17e4ca4c8e564cb846c
https://doi.org/10.1016/j.ijcard.2021.03.034
https://doi.org/10.1016/j.ijcard.2021.03.034
Autor:
PETER ROSSING, STEFAN ANKER, GERASIMOS FILIPPATOS, BERTRAM PITT, LUIS M. RUILOPE, VIVIAN FONSECA, GUILLERMO E. UMPIERREZ, LUIZA CARAMORI, MARC LAMBELET, PRABHAKAR VISWANATHAN, ROBERT LAWATSCHECK, AMER JOSEPH, GEORGE BAKRIS
Publikováno v:
Diabetes. 71
Introduction: Finerenone reduced risk of cardiorenal outcomes in patients with CKD and T2D in the FIDELIO-DKD and FIGARO-DKD studies. In FIDELIO-DKD the effects of finerenone on kidney and CV outcomes were consistent irrespective of glucagon-like pep
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::001f8a56e69b82f8048c950e213dc9d4
https://doi.org/10.2337/db22-22-or
https://doi.org/10.2337/db22-22-or
Autor:
Gerasimos Filippatos, Stefan D. Anker, Bertram Pitt, Peter Rossing, Amer Joseph, Peter Kolkhof, Marc Lambelet, Robert Lawatscheck, George L. Bakris, Luis M. Ruilope, Rajiv Agarwal
Publikováno v:
JACC. Heart failure. 10(11)
In patients with type 2 diabetes (T2D), risks of cardiovascular mortality and heart failure (HF) increase with decreasing kidney function (estimated glomerular filtration rate [eGFR]) and increasing albuminuria (urine albumin-to-creatinine ratio [UAC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3fb7d447658f296651e45d2d8aa65c9
https://pubmed.ncbi.nlm.nih.gov/36328655
https://pubmed.ncbi.nlm.nih.gov/36328655
Autor:
Gerasimos Filippatos, Rajiv Agarwal, Stefan D. Anker, Peter Rossing, Amer Joseph, Peter Kolkhof, Marc Lambelet, Marco A.L. Viaud, Luis M. Ruilope, George L. Bakris, Bertram Pitt
Publikováno v:
American Heart Journal. 254:254
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2e05afa3eda21ccac448a1be69f8f586
https://doi.org/10.1016/j.ahj.2022.10.055
https://doi.org/10.1016/j.ahj.2022.10.055